HIV and Pregnancy: General Information

Many women are concerned about how pregnancy could affect their HIV disease and about passing their HIV infection on to their babies. Recent studies have shown that with good prenatal care, use of anti-HIV medications and health care support, women living with HIV can have much-improved chances of having a healthy pregnancy and giving birth to healthy, HIV negative babies.

How does pregnancy affect HIV?

Studies have shown that pregnancy, by itself, does not speed up or slow down the course of HIV disease.

How does HIV affect pregnancy?

HIV infection does not appear to change the way a pregnancy normally progresses if the mother remains healthy.

The risk of complications increases for both the mother and baby if the mother develops an HIV-related opportunistic infection, such as Pneumocystis pneumonia (PCP), during pregnancy. This risk increases if the woman’s CD4+ count falls below 200.

HIV does not appear to affect the development of the unborn child. The main risk that HIV poses during pregnancy is the risk of infecting the baby. The average risk of mother-to-infant transmission in untreated women is about 20-25%. This risk can be greatly reduced (to 8-10%) by different ways, as discussed below.

Mother-to-baby HIV transmission

Mother-to-baby HIV transmission can occur at three stages:

- before birth
- during birth (labour and delivery)
- after birth through breast-feeding

Most researchers believe that transmission most commonly occurs during the last weeks of pregnancy or during delivery.

Factors that increase the risk of mother-to-baby transmission include:

- having a high viral load or low CD4+ (T-cell) count
- having a genital infection (like herpes) during pregnancy
- drinking alcohol, smoking cigarettes or using recreational/street drugs during pregnancy
- having the mother’s water “break” more than four hours before delivery
HIV and Pregnancy: General Information

- vaginal delivery
- difficult labour that requires cutting the vagina (episiotomy) and the use of forceps
- breast-feeding

Factors that decrease the risk of mother-to-baby transmission include:

- low/undetectable viral load and high CD4+ (T-cell) count
- use of anti-HIV medications
- elective Caesarian section for delivery
- active prevention of opportunistic infections
- active treatment of co-existing genital infections
- access to good prenatal care and health care services
- avoiding invasive investigative procedures during pregnancy
- no breast-feeding (bottle-feeding only)
- treatment of newborn with anti-HIV medications

Treatments to reduce and prevent mother-to-baby transmission

Anti-HIV medications

- The anti-HIV medication AZT (zidovudine) has been shown to reduce the risk of transmission from mother to baby. AZT is recommended for women during the last six months of pregnancy, during labour, and during delivery (by intravenous route), and for the baby during the first six weeks after birth.

- Other studies have shown that even when AZT is started later in pregnancy, or just around the time of delivery, it can still reduce the risk of transmission by about half.

- Recent studies showed a single dose of nevirapine (Viramune) given to the mother during labour and a single dose given to the baby after birth can also dramatically reduce the chances of mother-to-baby transmission.

Caesarean delivery

- The risk of transmission is reduced if the baby is delivered by planned Caesarean section rather than by vaginal delivery. This is called an “elective” C-section and is scheduled for the 38th week of pregnancy.

Anti-HIV medication treatment for pregnant women

Pregnant women with HIV are encouraged to take the treatment they require regardless of their pregnancy. The exceptions are the anti-HIV drugs efavirenz (Sustiva) and delavirdine (Rescriptor), which are not recommended during pregnancy. Using ddI and d4T together in a combination should also be avoided.

Guidelines for the general public about when to start anti-HIV medications also apply to pregnant women.

For more detailed information regarding anti-HIV medications for HIV positive women during pregnancy, please refer to the “Treatment guidelines for HIV positive women during pregnancy” fact sheet.

Information on the guidelines for the management of pregnant HIV positive women is available at the Canadian Medical Association website at http://www.cmaj.ca/cqi/collection/iv_infection_aids.
Decisions about particular medical treatments should always be made in consultation with a qualified medical practitioner knowledgeable about HIV-related illness and the treatments in question.

The Canadian AIDS Treatment Information Exchange (CATIE) in good faith provides information resources to help people living with HIV/AIDS who wish to manage their own health care in partnership with their care providers. Information accessed through or published or provided by CATIE, however, is not to be considered medical advice. We do not recommend or advocate particular treatments and we urge users to consult as broad range of sources as possible. We strongly urge readers to consult with a qualified medical practitioner prior to undertaking any decision, use or action of a medical nature.

We do not guarantee the accuracy or completeness of any information accessed through or published or provided by CATIE. Persons relying on this information do so entirely at their own risk. Neither CATIE nor the Public Health Agency of Canada nor any of their employees, directors, officers or volunteers may be held liable for damages of any kind that may result from the use or misuse of any such information. The views expressed herein or in any article or publication accessed or published or provided by CATIE are solely those of the authors and do not reflect the policies or opinions of CATIE or the views of the Public Health Agency of Canada.

Copyright: This Fact Sheet is made available through a collaboration between Asian Community AIDS Services (ACAS) and the Canadian AIDS Treatment Information Exchange (CATIE). Original content developed by ACAS, 2001.

This information is also available in French, Chinese, Tagalog, Vietnamese, Swahili, and other languages at languages.catie.ca and www.acas.org

Funding has been provided by the Public Health Agency of Canada.